文献速递头颈技术与安全PETCTMR

PET/CT与PET/MRI在头颈部恶性肿瘤中的应用

PET/CT and PET/MRI in head and neck malignancy.
PubMed 文献 · Clin Radiol · 2017-10-10

本文综述了FDG PET/CT在头颈部鳞状细胞癌分期(包括寻找原发灶、化疗后3-6个月疗效评估及鉴别复发与治疗效应)中的既定作用,提及PET NECK试验显示PET/CT引导监测与计划性颈清扫生存相似但监测更具成本效益,并讨论了缺氧示踪剂、68Ga肽类示踪剂及PET/MRI的应用前景。

要点

  • FDG PET/CT可用于头颈部鳞癌疑难病例分期、寻找原发灶及鉴别肿瘤复发与治疗效应。
  • PET NECK试验显示PET/CT引导监测与计划性颈清扫生存相似,且监测更具成本效益。
  • PET/MRI在头颈部鳞癌分期及后续疗效评估中可能比现有影像方法提供更高准确性。

核心结论

  • FDG PET/CT在头颈部鳞癌疑难病例分期、寻找原发灶、化疗后3-6个月疗效评估及鉴别复发与治疗效应方面有既定作用;PET/MRI可能比现有影像方法在头颈部鳞癌分期和后续疗效评估中提供更高准确性。

研究设计与样本

  • 综述性文章,未报告系统检索范围与纳入文献数量。

关键影像表现/征象

  • PET/MRI相比PET/CT具有解剖细节更丰富和辐射剂量降低的优势,并结合PET的分子与代谢数据。
  • PET/CT在显示肺转移瘤方面敏感性优于PET/MRI。
  • PET/CT与PET/MRI在原发灶、淋巴结、骨及软组织病灶的半定量测量之间具有高度相关性,两者一致性良好。

临床应用与阅片要点

  • PET/CT可用于头颈部鳞癌疑难病例分期、寻找原发灶、化疗后3-6个月疗效评估及鉴别疑似肿瘤复发患者的复发与治疗效应。
  • PET NECK试验显示,在晚期头颈部癌中,接受PET/CT引导监测的患者与接受计划性颈清扫的患者生存相似,但监测更具成本效益。
  • 缺氧PET示踪剂可用于靶向放疗,使缺氧区域的放疗剂量得以提升。
  • 68Ga肽类示踪剂可用于神经内分泌恶性肿瘤。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Combined 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT) has an established role in the staging of difficult cases of head and neck (HN) squamous cell carcinoma (SCC), looking for an unknown primary, assessing response post-chemotherapy at 3-6 months, and differentiating relapse from treatment effects in patients suspected to have tumour recurrence. The PET NECK trial, comparing PET/CT surveillance versus neck dissection in advanced head and neck cancer showed survival was similar among patients who underwent PET/CT-guided surveillance and those who underwent planned neck dissection, but surveillance was more cost-effective. There is growing interest in the use of hypoxia PET tracers, especially in targeting radiotherapy, where the radiotherapy dose can be boosted in regions of hypoxia; the use of 68Ga peptide tracers in neuroendocrine malignancy and also in the growing field of combined PET/magnetic resonance imaging (MRI). PET/MRI has the advantage of increased anatomical detail and radiation dose reduction combined with the molecular and metabolic data from PET, although PET/CT has the advantage in better sensitivity for imaging lung metastases. Thus far, there is good agreement between PET/CT and PET/MRI with high correlation between semi-quantitative measurements in primary, nodal, osseous, and soft-tissue lesions imaging. PET/MRI may indeed provide greater accuracy than the currently available imaging procedures in the staging and later treatment response evaluation in HNSCC.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Szyszko TA, Cook GJR. PET/CT and PET/MRI in head and neck malignancy. Clin Radiol. 2017. PMID: 29029767. doi:10.1016/j.crad.2017.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。